These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12021242)

  • 1. Leptin: a novel therapeutic role in lipodystrophy.
    Savage DB; O'Rahilly S
    J Clin Invest; 2002 May; 109(10):1285-6. PubMed ID: 12021242
    [No Abstract]   [Full Text] [Related]  

  • 2. Leptin-replacement therapy in lipodystrophy.
    Mauvais-Jarvis F
    N Engl J Med; 2002 Jun; 346(25):2008; author reply 2009-10. PubMed ID: 12075066
    [No Abstract]   [Full Text] [Related]  

  • 3. Leptin therapy in lipodystrophy.
    Savage DB; O'Rahilly S
    Diabetologia; 2010 Jan; 53(1):7-9. PubMed ID: 19802712
    [No Abstract]   [Full Text] [Related]  

  • 4. Leptin-replacement therapy in lipodystrophy.
    Inui A
    N Engl J Med; 2002 Jun; 346(25):2009; author reply 2009-10. PubMed ID: 12078706
    [No Abstract]   [Full Text] [Related]  

  • 5. Leptin-replacement therapy in lipodystrophy.
    Wolfsdorf J; Sadeghi-Nejad A; Senior B
    N Engl J Med; 2002 Jun; 346(25):2008-9; author reply 2009-10. PubMed ID: 12078705
    [No Abstract]   [Full Text] [Related]  

  • 6. Leptin and appetite control in lipodystrophy.
    Ahima R; Osei SY
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4254-7. PubMed ID: 15356017
    [No Abstract]   [Full Text] [Related]  

  • 7. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Cellular Bases of Lipodystrophy Syndromes.
    Zammouri J; Vatier C; Capel E; Auclair M; Storey-London C; Bismuth E; Mosbah H; Donadille B; Janmaat S; Fève B; Jéru I; Vigouroux C
    Front Endocrinol (Lausanne); 2021; 12():803189. PubMed ID: 35046902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myalept approved for treatment of disorders marked by loss of body fat.
    Morrow T
    Manag Care; 2014 Jun; 23(6):50-1. PubMed ID: 25109049
    [No Abstract]   [Full Text] [Related]  

  • 10. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy: pathophysiology and advances in treatment.
    Fiorenza CG; Chou SH; Mantzoros CS
    Nat Rev Endocrinol; 2011 Mar; 7(3):137-50. PubMed ID: 21079616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipodystrophies: adipose tissue disorders with severe metabolic implications.
    Cortés VA; Fernández-Galilea M
    J Physiol Biochem; 2015 Sep; 71(3):471-8. PubMed ID: 25833179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
    Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
    Gorden P; Park JY
    Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction.
    Maguire M; Lungu A; Gorden P; Cochran E; Stratton P
    Obstet Gynecol; 2012 Feb; 119(2 Pt 2):452-455. PubMed ID: 22270436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
    Miehle K; Stumvoll M; Fasshauer M
    Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
    Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
    J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of leptin therapy in the different forms of human lipodystrophy.
    Chong AY; Lupsa BC; Cochran EK; Gorden P
    Diabetologia; 2010 Jan; 53(1):27-35. PubMed ID: 19727665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.
    McDuffie JR; Riggs PA; Calis KA; Freedman RJ; Oral EA; DePaoli AM; Yanovski JA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4258-63. PubMed ID: 15356018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of leptin therapy in metabolic dysfunction.
    Park JY; Gavrilova O; Gorden P
    Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.